Adaptimmune
Develops therapies to treat cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $125m | Post IPO Debt | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 57 % | (98 %) | 253 % | 55 % | 342 % | 122 % | 195 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (125 %) | (11743 %) | (3179 %) | (2532 %) | (582 %) | (246 %) | (20 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (161 %) | (12225 %) | (3287 %) | (2571 %) | (609 %) | (189 %) | (40 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 165 % | 8690 % | 2313 % | 1807 % | 470 % | 210 % | 84 % |
Source: Company filings or news article
Related Content
Adaptimmune is a clinical-stage biopharmaceutical company specializing in the development of innovative cancer immunotherapy products. The company focuses on creating T cell therapies designed to target and treat solid tumors, aiming to transform the lives of cancer patients. Adaptimmune operates in the biopharmaceutical market, serving patients, healthcare providers, and research institutions. The business model revolves around research and development, clinical trials, and strategic collaborations with other biotech firms, such as their partnership with Genentech. Revenue is primarily generated through licensing agreements, milestone payments, and potential future product sales. The company is recognized as a top workplace in both the US and UK, emphasizing its commitment to a positive work environment.
Keywords: cancer immunotherapy, T cell therapy, solid tumors, biopharmaceutical, clinical trials, research and development, strategic collaborations, licensing agreements, milestone payments, innovative treatments.
Tech stack
Investments by Adaptimmune
Edit